KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
DALLAS, Jan. 25, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALYâ€) today announced an online corporate update scheduled for Wednesday next week on January 30, 2019. The presentation will include updates on KALY’s developments with Puration, Inc, (PURA) (“PURAâ€) and Generex Biotechnology, Inc. (GNBT). The presentation will also include updates on the company’s Hemp4mula product developments. The highlight of the presentation will feature the latest on the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD). KALY has completed an in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients. Favorable results prompted the launch of a physiological study whose results will be released later this quarter. The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
Goldman Small Cap Research Report published an
analyst research report on KALY on January 8th, 2019
that highlights KALY’s cannabis pharmaceutical value. The
report is available under “research†on the OTCMarkets website. The
research report is the first report from Goldman Small Cap Research
as part of an ongoing research engagement. The report outlines the
company’s current positioning and potential, upcoming milestones.
The report is intended to augment the current information available
on the OTCMarkets website. The report is also available to read or
download, along with associated disclosures and disclaimers,
at www.GoldmanResearch.com.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and as such, may involve risks and
uncertainties. These forward looking statements relate to, amongst
other things, current expectation of the business environment in
which the company operates, potential future performance,
projections of future performance and the perceived opportunities
in the market. The company's actual performance, results and
achievements may differ materially from the expressed or implied in
such forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
[email protected]
(214) 210-0459
